AstraZeneca (AZN) Submits NDA to U.S. FDA for Ticagrelor
More News related to AZN
- AstraZeneca (AZN) Gets Additional Approval from U.S. FDA for CRESTOR
- US FDA Approves New Indication for CRESTOR(R) (rosuvastatin calcium)
- Atlantis(TM) Patient-Specific Abutment Now Available for NobelActive(TM) Implants
- AstraZeneca (AZN) Biz Unit MedImmune Announces Publication of Pivotal Trial for Motavizumab
- Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
AstraZeneca (NYSE: AZN) today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The proposed trade name for ticagrelor is BRILINTA, pending approval from the FDA.
This submission is based on the results of a comprehensive program, including data from PLATO (A Study of Platelet Inhibition and Patient Outcomes), the Phase III head-to-head trial comparing ticagrelor plus aspirin with clopidogrel (Plavix) plus aspirin.
Related Categories
Corporate NewsStocks Mentioned
+0.98Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
